Category Archives: Stem Cell Treatment


Gene Therapy Reverses Heart Failure in Mouse Model – Technology Networks

Barth syndromeis a rare metabolic disease caused by mutation of a gene calledtafazzinorTAZ. It can cause life-threatening heart failure and also weakens the skeletal muscles, undercuts the immune response, and impairs overall growth. Because Barth syndrome is X-linked, it almost always occurs in boys. There is no cure or specific treatment.

In 2014, to get a better understanding of the disease,William Pu, MD, and colleagues at Boston Childrens Hospital collaborated with the Wyss Institute to create a beatingheart on a chip model of Barth syndrome. The model used heart-muscle cells with theTAZmutation, derived from patients own skin cells.It showedthatTAZis truly at the heart of cardiac dysfunction: the heart muscle cells did not assemble normally, mitochondria inside the cells were disorganized, and heart tissue contracted weakly. Adding a healthyTAZgene normalized these features, suggesting that gene replacement therapy could be a viable treatment.

But to fully capture Barth syndrome and its whole-body effects, Pu and colleagues needed an animal model. The animal model was a hurdle in the field for a long time, says Pu, director of Basic and Translational Cardiovascular Research at Boston Childrens and a member of the Harvard Stem Cell Institute. Efforts to make a mouse model using traditional methods had been unsuccessful.

As described in the journalCirculation Research, most mice with the whole-bodyTAZdeletion died before birth, apparently because of skeletal muscle weakness. But some survived, and these mice developed progressive cardiomyopathy, in which the heart muscle enlarges and loses pumping capacity. Their hearts also showed scarring, and, similar to human patients with dilatedcardiomyopathy, the hearts left ventricle was dilated and thin-walled.

Mice lackingTAZjust in their cardiac tissue, which all survived to birth, showed the same features. Electron microscopy showed heart muscle tissue to be poorly organized, as were the mitochondria within the cells.

Pu, Wang, and colleagues then used gene therapy to replaceTAZ, injecting an engineered virus under the skin (in newborn mice) or intravenously (in older mice). Treated mice with whole-bodyTAZdeletions were able to survive to adulthood.TAZgene therapy also prevented cardiac dysfunction and scarring when given to newborn mice, and reversed established cardiac dysfunction in older mice whether the mice had whole-body or heart-onlyTAZdeletions.

Thats where the challenge will lie in translating the results to humans. Simply scaling up the dose of gene therapy wont work: In large animals like us, large doses risk a dangerous inflammatory immune response. Giving multiple doses of gene therapy wont work either.

The problem is that neutralizing antibodies to the virus develop after the first dose, says Pu. Getting enough of the muscle cells corrected in humans may be a challenge.

Another challenge is maintaining populations of gene-corrected cells. While levels of the correctedTAZgene remained fairly stable in the hearts of the treated mice, they gradually declined in skeletal muscles.

The biggest takeaway was that the gene therapy was highly effective, says Pu. We have some things to think about to maximize the percentage of muscle cell transduction, and to make sure the gene therapy is durable, particularly in skeletal muscle."

Reference: Wang et al. (2020).AAV Gene Therapy Prevents and Reverses Heart Failure in A Murine Knockout Model of Barth Syndrome.Circulation Research.https://www.ahajournals.org/doi/abs/10.1161/CIRCRESAHA.119.315956.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Read the original here:
Gene Therapy Reverses Heart Failure in Mouse Model - Technology Networks

CytoDyn Files Modified IND and Protocol for Phase 2 Clinical Trial for Treatment of Patients with Coronavirus with Leronlimab (PRO 140) and Advises…

VANCOUVER, Washington, March 16, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (CytoDyn or the Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the Company filed a modified IND and protocol for its Phase 2 clinical trial with leronlimab (PRO 140) as a therapy for patients who experience respiratory complications as a result of contracting Coronavirus Disease 2019 (COVID-19). The modification came at the behest of the U.S. Food and Drug Administration (FDA) in response to the Companys filing of its IND and protocol for its Phase 2 clinical trial on March 9, 2020.

The modified protocol is a Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Leronlimab in Patients with Coronavirus Disease 2019 (COVID-19) and calls for 75 planned patients in up to 10 centers in the United States. Patients enrolled in the trial are expected to have a treatment window of approximately 6 weeks.

Jacob Lalezari, M.D., CytoDyns Interim Chief Medical Officer commented: We appreciate the FDAs timely input on protocol design and hope to start the treatment study in the very near future.

Nader Pourhassan, Ph.D., president and chief executive officer of CytoDyn said: We are pleased with the new trial design and are rapidly sending supplies of leronlimab to the clinics to begin patient treatment.

With respect to the Companys press release issued on March 12, 2020, management announces the following correction: Patient #1 had missed one treatment of carboplatin and will continue to be treated with carboplatin and leronlimab. Additional updates about this patient will be included in the next Company update on all cancer patients.

About Leronlimab (PRO 140) The U.S. Food and Drug Administration (FDA) have granted a Fast Track designation to CytoDyn for two potential indications of leronlimab for deadly diseases. The first as a combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer. Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases including NASH. Leronlimab has successfully completed nine clinical trials in over 800 people, including meeting its primary endpoints in a pivotal Phase 3 trial (leronlimab in combination with standard anti-retroviral therapies in HIV-infected treatment-experienced patients).

In the setting of HIV/AIDS, leronlimab is a viral-entry inhibitor; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. Leronlimab has been the subject of nine clinical trials, each of which demonstrated that leronlimab can significantly reduce or control HIV viral load in humans. The leronlimab antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements compared with daily drug therapies currently in use. In the setting of cancer, research has shown that CCR5 plays an important role in tumor invasion and metastasis. Increased CCR5 expression is an indicator of disease status in several cancers. Published studies have shown that blocking CCR5 can reduce tumor metastases in laboratory and animal models of aggressive breast and prostate cancer. Leronlimab reduced human breast cancer metastasis by more than 98% in a murine xenograft model. CytoDyn is therefore conducting aPhase 1b/2 human clinical trial in metastatic triple-negative breast cancer and was granted Fast Track designation in May 2019. Additional research is being conducted with leronlimab in the setting of cancer and NASH with plans to conduct additionalclinical studies when appropriate.

The CCR5 receptor appears to play a central role in modulating immune cell trafficking to sites of inflammation and may be important in the development of acute graft-versus-host disease (GvHD) and other inflammatory conditions. Clinical studies by others further support the concept that blocking CCR5 using a chemical inhibitor can reduce the clinical impact of acute GvHD without significantly affecting the engraftment of transplanted bone marrow stem cells. CytoDyn is currently conducting a Phase 2 clinical study with leronlimab to further support the concept that the CCR5 receptor on engrafted cells is critical for the development of acute GvHD and that blocking this receptor from recognizing certain immune signaling molecules is a viable approach to mitigating acute GvHD. The FDA has granted orphan drug designation to leronlimab for the prevention of GvHD.

About CytoDynCytoDyn is a biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a key role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor metastasis and in immune-mediated illnesses, such as GvHD and NASH. CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard anti-retroviral therapies in HIV-infected treatment-experienced patients. CytoDyn plans to seek FDA approval for leronlimab in combination therapy and plans to complete the filing of a Biologics License Application (BLA) in the first quarter of 2020 for that indication. CytoDyn is also conducting a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients and plans to initiate a registration-directed study of leronlimab monotherapy indication, which if successful, could support a label extension. Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs). Moreover, results from a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients, with some patients on leronlimab monotherapy remaining virally suppressed for more than five years. CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for the prevention of GvHD and a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. More information is atwww.cytodyn.com.

Forward-Looking StatementsThis press releasecontains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as believes, hopes, intends, estimates, expects, projects, plans, anticipates and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. The Companys forward-looking statements are not guarantees of performance, and actual results could vary materially from those contained in or expressed by such statements due to risks and uncertainties including: (i)the sufficiency of the Companys cash position, (ii)the Companys ability to raise additional capital to fund its operations, (iii) the Companys ability to meet its debt obligations, if any, (iv)the Companys ability to enter into partnership or licensing arrangements with third parties, (v)the Companys ability to identify patients to enroll in its clinical trials in a timely fashion, (vi)the Companys ability to achieve approval of a marketable product, (vii)the design, implementation and conduct of the Companys clinical trials, (viii)the results of the Companys clinical trials, including the possibility of unfavorable clinical trial results, (ix)the market for, and marketability of, any product that is approved, (x)the existence or development of vaccines, drugs, or other treatments that are viewed by medical professionals or patients as superior to the Companys products, (xi)regulatory initiatives, compliance with governmental regulations and the regulatory approval process, (xii)general economic and business conditions, (xiii)changes in foreign, political, and social conditions, and (xiv)various other matters, many of which are beyond the Companys control. The Company urges investors to consider specifically the various risk factors identified in its most recent Form10-K, and any risk factors or cautionary statements included in any subsequent Form10-Q or Form8-K, filed with the Securities and Exchange Commission. Except as required by law, the Company does not undertake any responsibility to update any forward-looking statements to take into account events or circumstances that occur after the date of this press release.

CYTODYN CONTACTSInvestors: Dave Gentry, CEORedChip CompaniesOffice: 1.800.RED.CHIP (733.2447)Cell: 407.491.4498dave@redchip.com

View original post here:
CytoDyn Files Modified IND and Protocol for Phase 2 Clinical Trial for Treatment of Patients with Coronavirus with Leronlimab (PRO 140) and Advises...

Heartbreaking coronavirus reality as isolated mum’s daughter waves at her from street – Mirror Online

A mum has laid bare the devastating reality of coronavirus by sharing a picture of her young daughter waving at her from the street as she self-isolates.

Dr Laura Noonan has a rare blood disease and needs a type of chemotherapy and stem cell treatment unavailable in Ireland.

TheGP, who travels to Russia every three to four months, is now in a Dublin hospital and fears the coronavirus could kill her.

Dr Noonan, who had just left out of an Intensive Care Unit for her prior health difficulties, said: Im back to the normal ward now, but I dont feel safe at all here.

I think Ill be be exposed to coronavirus through staff even [though there are] no visitors allowed.

I wanted to share with you what I think is the most powerful and impactful image I have seen that represents lockdown Ireland through the eyes of a child."

Mrs Noonan, who said she misses her daughter terribly, added to the Irish Mirror : "Thats my little girl [Freya] and mother waving up to me in isolation on the second floor of the hospital from the footpath below."

The patient, who has been travelling to Russia since January 2018, continued: "She is only seven. We cant see each other because of Covid-19 visiting restrictions.

Mrs Noonan said: "Thisis the face and bravery of one child in the midst of the coronavirus pandemic.

This is possibly one of the saddest photos I have ever taken.

My mother and Freya, two of the strongest women I know, standing outside the hospital waving up at me, talking on the phone and even trying to take a family selfie from a two-storey height difference.

This is not the first time we have had visits through the glass of a hospital window.

We grew very accustomed to that but it was very different that time.

There was a defined period it would last for and I knew when my numbers picked up enough I would be reunited with them albeit with each of us gowned and masked.

This is so different. This time there is no defined period."

Thousands of patients in Irish hospitals by the visiting bans that have been imposed since the coronavirus outbreak.

And Dr Noonan added: "My family have been called to say their goodbyes a few times.

"My brother and sister-in-law had to take an emergency visa to get out to me when I was really sick abroad.

Two weekends ago my husband [Archie] thought I wasnt going to wake from the coma and I did.

I was almost angry at first as I thought I was only living to die another day and I had already put up with so much I couldnt face anymore, but perspective changed over the next few days and Im ready to fight for my daughter again.

"But coronavirus has me terrified again."

Ironically, Mrs Noonan was on a flight from Russia to Ireland on February 2 when officials in hazmat suits removed a suspected coronavirus victim from the plane.

She said: We were all given a leaflet stating that we had possibly been exposed and a list of symptoms to watch out for over the following days.

It also advised we go straight to our onward destinations with as little contact with other people as possible and wait to hear from a doctor the next day.

A public health doctor and some paramedics came onto the plane and distributed contact forms for us to fill in.

It was about two hours after we landed before we got that much info.

But we all knew what the possible problem was within 10 minutes of landing as a paramedic in a hazmat suit removed a Chinese passenger from the plane."

That passenger subsequently tested negative for coronavirus, but if Mrs Noonan does contract the virus it could potentially be fatal for her.

Mrs Noonan said she has no idea when she will see her family.

She added: "I don't know how long I will be looking at my family through a pane of glass or on a video call of some type.

"Im lucky Im able to have my phone and use it.

"Many times, even during this admission, I didnt have my phone as I was too sick to manage it.

"I am always in isolation in hospital due to my lack of a functioning immune system from the chemo and other medications.

"But I could see my close family once they strictly adhere to the hygiene rules and wear masks, gloves and aprons/gowns as directed.

This time I cant see anyone.

Nobody [is allowed] in or out of the hospital without security clearance.

This time it was sprung on us with no real warning. I was told along the grapevine on Friday that no more visitors were allowed.

That was it. There was no time to gather up stuff to bring in to me.

Simple things like toiletries and clean pyjamas and family have since dropped things to the reception, which have been passed on after being sanitised, but its very hard to know they are in the building and I still cant see them even for a minute."

Read more from the original source:
Heartbreaking coronavirus reality as isolated mum's daughter waves at her from street - Mirror Online

Week In Review: Nanjing Legend Files To Stage IPO In The U.S. – Seeking Alpha

Deals and Financings

Nanjing Legend Biotech, a subsidiary of GenScript (HK: 1548) (OTC:GNNSF), has filed for an IPO on a US exchange. In 2017, Legend surprised the world when its CAR-T therapy produced a 94% response rate in pretreated multiple myeloma patients. Six months later, Johnson & Johnson (NYSE:JNJ) partnered the treatment in a deal that paid Legend $350 million upfront, plus unspecified milestones and royalties. The CAR-T candidate, JNJ-4528, is now in Phase II trials in the US.

Harbour BioMed (HBM) raised $75 million in a Series B+ round to advance its clinical-stage compounds and portfolio of next-gen biotherapies for cancer and immunological diseases. The company builds its portfolio by in-licensings and via its proprietary Harbour Mice program. Harbour develops drugs for China and US markets, while it has entered partnerships to discover candidates for China companies Innovent (OTCPK:IVBIY) and BeiGene (NASDAQ:BGNE), along with other prominent global biopharmas. The company previously completed an $85 million Series B financing in August 2018. HBM is headquartered in Cambridge, MA, and it conducts R&D in Suzhou and Shanghai.

GenFleet Therapeutics (Shanghai) closed a $57 million Series B financing, co-led by CDH Investments and Shenzhen Capital Group. Founded in 2017, GenFleet is developing novel large and small therapeutic molecules for oncology and immunology targets. The company says its projects are potential first-in-class therapeutics with technical advantages and large markets. It will use the capital for ex-China development and clinical trials of its existing pipelines, plus expanding its immunology platform, working on new projects and building an industrial base.

Arctic Vision of Shanghai in-licensed greater China rights to Xipere, a treatment for macular edema associated with uveitis, from Clearside Bio (NASDAQ:CLSD) in a $35.5 million agreement. Founded last year, Arctic in-licenses breakthrough ophthalmology products for China. Xipere is its first deal. Arctic plans to acquire China rights to 3-5 products and then expand to a combination of global rights and internal discovery for additional drugs. Clearside, which is located in Alpharetta, Georgia, said Xipere is a proprietary suspension of the corticosteroid triamcinolone acetonide.

Exuma Biotech (formerly F1 Oncology), a Florida-Shanghai company developing CAR-T products for solid tumors, closed a $19 million Series B round. The financing included investments from MSD Partners and F1 BioVentures, plus conversion of notes held by individual investors. Exuma's Logic Gated CAR-T products become activated only when the target antigen and the tumor microenvironment are both present, reducing off-tumor side effects. The company has started clinical trials of two candidates. Exuma's Shanghai subsidiary oversees the company's development, manufacturing, and commercial units in Shanghai and Shenzhen.

OBiO Technology (Shanghai) completed a B+ Round of more than $15 million for its viral-based gene therapy CRO services and genetic drug CDMO/CMO services. Founded in 2013, OBiO collaborated with GE Healthcare (NYSE:GE) to establish the first domestic GMP viral production workshop in China and supply CRO/CDMO/CMO services for viral drugs. At the same time, OBiO is incubating gene therapy drugs for cancer therapy with three ADC candidates for oncotherapy that have proprietary IP. The B+ Round investors included GP Capital, Sinowisdom and Efung Capital.

Shanghai OPM Biosciences raised $14 million from China Life Medical Fund to support its CDMO service platform. The company offers serum-free media for cell cultures based on animal cells, as well as a full-range of cell culture development services. It customizes high-quality personalized animal cell culture media to optimize the cell culture process and reduce production costs. OPM has developed a variety of chemically defined CHO/HEK293 cell culture media and nutritional products. The company claims its media improve cell growth and expression.

China Immunotech Biotech of Beijing completed a $6.5 million Series A financing, led by Jianxin Capital with Grower Venture Capital and Huacheng Group participating. Founded in March 2018, China Immunotech is developing TCR-T and CAR-T products that target hematological tumors, solid tumors and virus-related diseases. It has two unique technology platforms, STAR-T and TCR-T. The STAR-T platform uses a proprietary structure of antigen receptor complexes. The company believes the platform provides multi-targeted molecules with better efficacy, fewer side effects and easier development than traditional CAR-T products.

Chengdu's HitGen has signed a licensing agreement to develop a novel class of drugs for Kaken, a Japanese (TK: 4521) specialty pharma. HitGen has already used its large library of small molecule and macrocyclic compounds to identify potential candidates. Few details were released, but Kaken is known to be concentrating its R&D on inflammation/immunology (dermatitis, rheumatoid arthritis and osteoarthritis), pain relief and fungal infections. One year ago, the two companies formed a similar collaboration, presumably for other targets. HitGen will receive an upfront payment and be eligible to receive preclinical and clinical milestones.

Suzhou Ascentage Pharma (HK: 6855) announced approvals for three clinical studies of APG-2575, a novel Bcl-2 inhibitor, two in the US and one in China. APG-2575 is an oral drug designed to treat several hematologic malignancies by blocking Bcl-2 to restore the normal apoptosis process in cancer cells. According to Ascentage, the candidate is the first China-made Bcl-2 inhibitor to start clinical trials. In its Phase I clinical studies, APG-2575 did not exhibit any dose-limiting toxicity or tumor lysis syndrome (which is commonly associated with other Bcl-2 inhibitors).

Denovo Biopharma, a San Diego-Beijing precision medicine company, has discovered a novel genetic biomarker for depression that it intends to use with DB104, a triple dopamine, serotonin and norepinephrine reuptake inhibitor. The company made the discovery using its proprietary biomarker discovery platform. Denovo licensed DB104 from Albany Molecular Research. Bristol-Myers Squibb (NYSE:BMY) returned the candidate to Albany after two Phase IIb clinical trials in treatment-resistant depression. The biomarker is one of four DeNovo biomarkers aimed at psychiatric use.

I-Mab (NASDAQ:IMAB), a Shanghai clinical-stage biopharma, has started to develop TJM2 (TJ003234) to treat cytokine release syndrome in severe cases of COVID-19. TJM2 is an I-Mab-discovered neutralizing antibody that binds human granulocyte-macrophage colony stimulating factor (GM-CSF), an important cytokine that plays a critical role in acute and chronic inflammation. By binding GM-CSF, TJM2 prevents downstream signaling and target cell activation, inhibiting other inflammatory responses. I-Mab intends to start clinical trials in the US and expand to countries especially hard-hit by COVID-19.

Mesoblast (NSDQ: MESO; ASX: MSB), an Australia-based regenerative medicine company, announced plans to start trials of remestemcel-L, its allogeneic mesenchymal stem cell (MSC) product candidate, in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19. The trial will be conducted in the US, Australia, China and Europe. ARDS is the principal cause of death in COVID-19 patients. In a small China trial, allogeneic MSCs cured or significantly improved all seven patients with severe COVID-19 pneumonia.

Ascletis (HK: 1672), a Hangzhou biopharma, reported that an initial group of 11 COVID-19 patients all recovered after being treated with a combination Ganovo and Ritonavir therapy. Ascletis's Ganovo, the first approved direct-acting anti-viral agent developed by a China company, was launched in 2018 to treat hepatitis C. Ritonavir is a generic anti-retroviral that is used in AIDS/HIV combination therapies. The small clinical trial was led by Dr. Hongyi Chen, the director of the Ninth Hospital of Nanchang.

Disclosure: None

Original Post

Editor's Note: The summary bullets for this article were chosen by Seeking Alpha editors.

Originally posted here:
Week In Review: Nanjing Legend Files To Stage IPO In The U.S. - Seeking Alpha

Stem Cell Injections: What Are They & Does Stem Cell Therapy Work

The headlines sound almost too good to be true: Researchers Stunned by Stem Cell Experiment That Helped Stroke Patient Walk; Wife Recovered From Cancer After Pioneering Stem Cell Treatment; Stem Cell Transplant Trial Has Miraculous Effect on Multiple Sclerosis Sufferers.

Indeed, even experts are excited about these miracle cells, which are abundant in the body and can repair and replace all kinds of tissue. Theres no doubt in my mind that stem cells are going to revolutionize the way medicine is practicedwith the same kind of impact that antibiotics and vaccinations hadgetting at the root causes of disease rather than dancing around the periphery, says Charles Murry, M.D., Ph.D., director of the Institute for Stem Cell and Regenerative Medicine at the University of Washington in Seattle.

But when it comes to medical research, Dr. Murry cautions, stem cells are barely at the starting gate. Despite their hitting the petri dish more than 20 years ago, many big questions remain: Which people, with which diseases, might benefit from their use? What types of stem cells should be used? How can the cells be manipulated and administered for lasting effect? And how does the treatment work? Exciting as the clinical trials are, most of those that have been completed so far are just at the phase one stage, in which researchers test a small number of people to see if an intervention is safe, not yet whether its effective.

What actually is too good to be true, then, are the claims being made by many of the for-profit stem cell clinics that have proliferated in the U.S. (more than 700 and counting). Using nothing more than very early study results and testimonials, these clinics promise thatfor thousands or tens of thousands of dollarsthey can use your own stem cells to treat everything from MS and rheumatoid arthritis to heart disease, diabetes, damaged joints, and cancer. Some offer cosmetic stem cell face-lifts or cellular breast and buttock jobs; others promise to boost athletic prowess.

Theres a striking gap between the claims these centers are making and the research thats been done for most of these diseases, says Leigh Turner, Ph.D., an associate professor in bioethics at the University of Minnesota who studies these clinics. People need to be very cautious about this treatment right now.

Most of the cells in our bodies are specific types of cellsheart, lung, muscle, nerve, blood, and more. But stem cells are undifferentiated, which means they have the potential to turn into more stem cells or other types of cells. Stem cells also can divide indefinitely and replace worn-out tissue, giving them the ability to become other cells and the potential to act as a ready repair system for the body.

What it's like to have stem cells injected into your face for younger-looking skin:

Stem cells generate so much buzz because they have the unique ability to turn into different types of cells. This means they have the potential to rebuild organs that are diseased, which in the medical field is known as regenerative medicine. Early on, scientists focused on stem cells taken from embryos because those cells naturally transform into the myriad ones that develop into the babys tissues and organs. But ethical issues and federal regulations related to these cells sent researchers scrambling to find alternatives.

Today, cutting-edge scientists are working to coax adult blood cells to become nascent cells akin to the embryonic kind by adding certain DNA molecules. These induced pluripotent stem cells, which have shown early promise, generally require months of careful manipulation in a lab and thus are mainly limited to top medical centers. Most of the for-profit clinics have settled on using cells taken from fully developed tissue, known as adult stem cells. By using cells from a persons own body, these clinics can complete a treatment in a day or a few weeks. Doctors typically liposuction a little fat or remove some bone marrow (which is an especially rich source of stem cells), put it through a few steps to remove other tissue, then inject the stem cells where they want them to proliferate. Someone whos coming in with arthritic hip pain, for example, might have cells removed from her belly and inserted into her hip.

Critics say the for-profit clinics that currently claim they can treat all manner of disease with adult stem cells are not being honest. Much more study is needed before any of these claims can be substantiated, says Kapil Bharti, Ph.D., a research scientist at the National Eye Institute of the National Institutes of Health who is at the leading edge of research on using pluripotent cells to treat macular degeneration. The problem with the cells is what we dont know. Those clinics inject the cells and hope they will secrete something beneficial, but every time they do the injections, theyre rolling the dice, he says.

The scientific consensus is that stem cells taken from fat or bone marrow are not as malleable as embryonic cells, meaning that rather than turn into completely different cells, they mostly create more of the same tissue. There is zero evidence, for example, that bone marrow tissue can make eye tissue, even though many of these clinics say it can. The cells dont integrate, so they die off, Bharti saysand the injections may cause significant damage in the process.

At the moment, stem cell treatments are medically recommended only for a small number of blood disorders. To treat leukemia, for example, patients typically have their bone marrow harvested before their bodies are blasted with high-dose chemotherapy. The stem cells from the marrow are then reinserted into the bloodstream to restore damaged cells there.

Early-stage research involving other conditions reveals why physicians are so excited about the methods future prospects. A very small industry-funded clinical trial in Australia found that in people who had the anterior cruciate ligament (ACL) in the knee reconstructed, those who subsequently had stem cells injected into their knees had less pain and better physical results on their MRIs than did a control group. An ongoing multiyear study of 110 patients with relapsing-remitting MS is finding that those treated with stem cells from their own bone marrow (along with some chemotherapy and/or radiation) are much less likely to have their disability worsen than those on standard disease-modifying drugsan incredible 6% versus 60%.

The potential to help her severe MS was what drove SammyJo Wilkinson of Edmonds, WA, to seek out stem cell treatment from a for-profit clinic in 2012. Wilkinson was desperate for something that might improve a disease that had forced her to shutter her thriving technology company and go on disability a decade earlier. After researching clinics, she settled on one in Texas (later relocated to Mexico). She liked that the clinic was up-front that the procedure was experimental and that her stem cells were banked for future rounds.

Six years and five treatments later, Wilkinson is happy with the results, even though major symptoms, including blindness in her right eye and the inability to walk without a wheelchair, remain. But of the 28 symptoms she said had decimated her life, 17 have disappeared, from fatigue and brain fog to numbness in her hands. My quality of life is so much better. No current medication can do what this treatment did, she says. Still, when other women with MS call her for advice, she lets them know that she is not curedand that the cost of her treatments ($90,000 plus travel expenses, none of it covered by insurance) was staggering.

While Wilkinson was lucky that she had positive results, this isnt true for many others. Thats one reason stem cell scientists are angry that the Food and Drug Administration hasnt come down harder on for-profit clinics. Between 2011 and 2017, the FDA issued some warning letters, and the Department of Justice filed for injunctions against only two clinics (one with multiple locations) this past May. In December 2018, the FDA issued yet another warning after 12 patients fell seriously ill after receiving stem cell injections. Litigation is ongoing, although the clinics can still see patients.

For-profit clinics point out that the FDA differentiates between drugs that need to go through the multiyear, multimillion-dollar approval process and those that use minimally manipulated substances taken from a persons own body, which dont. The clinics claim their treatments fall into the latter category, though critics say theyre manipulated much more heavily than the FDA intended for nondrug treatments. This has come to be a really important line, and many for-profit businesses claim theyre on the right side of it when realistically they arent, says Paul S. Knoepfler, Ph.D., a professor at the UC Davis School of Medicine who runs The Niche (ipscell.com), a blog that sheds light on the industry.

It might seem that theres no danger in receiving a treatment using your own cells, but that isnt the case. People have suffered very serious complications, Turner says. An article in Nature counts nine lawsuits in which people alleged that their treatmentsfor diabetes, lupus, lung disease, cosmetic surgery, and morecaused them harm. A report in the New England Journal of Medicine described three women with macular degeneration whose vision significantly worsened (two are now legally blind) when stem cells harvested from belly fat were injected into their eyes. Several stem cell clinic patients have died.

And those are just the people we know aboutside effects and serious complications dont have to be reported by the clinics, Turner says. Whats more, once-promising treatments have been shown to be potentially dangerous. Doctors were initially excited to think stem cells might repair diseased hearts, but a 2017 study on mice found that when the cells were injected, they turned inflammatory and worsened heart disease. (More research is being done.)

Another big issue is money. The fees Wilkinson paid are typical, and even cheaper therapies can feel like a rip-off. Although one injection of stem cells several years ago helped Olympic track and field hurdler LaVonne Idlette heal tendinitis in her knee, when she went back to treat a pulled hamstring muscle, another injection did nothing. At $1,200 a shot, it was ridiculously expensive, says the 32-year-old Miami resident, now an attorney.

If you want to look into stem cell treatment, experts say the best way is to ask your doctor whether any reputable medical centers are conducting clinical trials focused on your disease. You can find trials at the National Institutes of Healths website clinicaltrials.gov, but theres another caveat: Some clinics say theyre doing a patient-funded study, and theyll even list it on the government website, but when you look at the details, there are a lot of red flags, Turner says. One of those is being asked to pay thousands of dollars to participate (reputable studies typically ask only that you pay your own travel fees). Turner also doubts that data from these so-called trials are being tabulated; he and others say some clinics are simply trying to legitimize risky treatments.

Beyond entering a trial youre sure is being done properly, experts say that for now you should steer clear. Mayo Clinic has started a regenerative medicine consult service and tells patients this: The current standard of care for nearly all medical conditions is still the best. If you have arthritis in your knees, for example, physical therapy, medication, or even knee replacement surgery will give you much better odds than experimental stem cell treatments, says Shane Shapiro, M.D., program director at Mayo Center Regenerative Medicine Therapeutic Suites.

Of course, clinics point to success stories as reasons to try their stem cell therapies. Seven years ago, Amy Klein, a freelance writer in New York City, received a stem cell face-lift to get rid of a tired complexion and dark bags under her eyes. Stem cells were taken from her stomach fat and injected into her face. So many years later, my skin still looks really good. Not only are my bags gone, but the quality of my skin is back to the dewy tightness of my youth, she says.

But when small numbers of patients claim good results, scientists call it anecdotal medicine and stress that its not strong enough evidence to base treatment advice on. Before you can call something a success, you have to repeat your findings with a large number of patients over a long period of time, Dr. Shapiro says. Until those major studies are done and its proven that stem cells are safe and effective for the conditions for which theyre being advertised, patients are simply rolling the dice.

Despite warnings, some patients with serious degenerative diseases who have tried all the conventional treatments choose for-profit stem cell clinics. If someone thinks its better to take a low-percentage shot as opposed to waiting for a degenerative disease to progress, that may not be an entirely irrational way to view things, says Dr. Murry. The problem is, its nearly impossible for the average patient to evaluate whether an unproven treatment has evidence for safety or efficacy. This is why the clinics need regulatory oversight.

How to protect yourself if you do decide to proceed:

See what the evidence shows. The federal database pubmed.gov lists results of most published studies. If you read reputable journals to see what the evidence reveals, youll be less likely to fall prey to a clinics overselling. If theres zero research on the use of stem cells for your condition, be especially concerned.

Know that some treatments are riskier than others. Procedures that inject cells into vital organs, like the brain, nervous system, heart, or eyes, have the potential to do more serious damage if the treatment goes awry than those aiming to fix joints or appearance.

Choose a clinic with care. If they tell you a treatment theyre selling has no risks, thats a big red flag: Theyre either woefully lacking in knowledge or not being honest, and I would walk away, says Paul S. Knoepfler, Ph.D. Keep your doctor informed. Youll want to let your physician know youre planning to do this, then see him or her soon after your treatment, Dr. Murry advises.

See the original post here:
Stem Cell Injections: What Are They & Does Stem Cell Therapy Work

Does Medicare Cover Stem Cell Therapy in 2020? Find Out Here

Stem cell therapy has revolutionized the healthcare system. It has provided hopes for patients who suffer from diseases that were considered incurable and even some other acute and chronic diseases that had a lesser chance of recovery.

It can relieve the symptoms the patients are experiencing and also enhance the quality of their life. Here is a brief discussion about whether stem cell theory is covered by Medicare.

Medicare Plan A and B cover the costs of stem cell therapies when certain criteria are fulfilled. However, even in these cases, Medicare does not reimburse the full costs.

Stem cell therapies that involve blood-forming stem cells are approved by the FDA. And hence, only these therapies would be covered by Medicare. There are certain limits to the coverage of stem cells therapies depending on the types of stem cells used as discussed beneath:

Stem cells are the cells that are formed in the body at birth. The uniqueness of these cells is they can change into any type of cell found in any organ or tissue of the body. These cells have the ability to regenerate and form more cells of a similar type to heal the damaged tissues and organ. These cells play an important role in producing organs, ligaments, bones, muscles, tendons, joints and skin.

There are basically 4 main types of stem cells that the body can produce during its life.

HSCT or Hematopoietic Stem Cells are also a type of stem cell. Stem cell therapies using these cells would be covered by Medicare only when it is performed for conditions such as:

Autologous Stem Cell Transplantation is covered by Medicare Plan A and B when it is recommended for the management of the following conditions:

Stem Cell Therapy is not covered by Medicare to treat the following conditions:

When stem cell therapy is performed for the management of these conditions, it would not be covered by Medicare Plan A or B. For example; though Stem cell therapy is considered effective for the management of osteoarthritis of the knee joint, it is not covered by Medicare as it is not approved by the FDA,

Medicare beneficiaries who experience chronic pain due to osteoarthritis can check whether any other insurance plan covers the expenses of stem cell therapy.

They can check the coverage offered by Medicare Advantage Plans and sign up for one if they anticipate they might need to undergo the procedure in the future. They should also check the specific criteria that must be fulfilled in order to be eligible for the coverage.

Link:
Does Medicare Cover Stem Cell Therapy in 2020? Find Out Here

Stem Cell Therapy | Stanford Initiative to Cure Hearing Loss

What if doctors could grow a new working inner ear from a persons own skin cells? Or repair the damaged inner ear from within?

Solving this profound mystery is the driving force behind stem cell research and the promise of tissue engineering in otolaryngology. While hearing aids and cochlear implants can provide good recovery of hearing function, the development of a biological method to repair the damaged cochlea has the potential to restore normal hearing without any type of prosthesis.

One approach to restore hearing might be to surgically place stem cells within the cochlea in such a way that they would fuse with the remaining cochlear structures and develop and function as hair cells. Scientists believe this is a viable approach because, unlike most organs that are destroyed by disease, the inner ear remains structurally intactonly the hair cells are lost. By mimicking the steps involved in the formation of embryonic mouse ears, Stanford scientists have produced stem cells in the laboratory that look and act very much like hair cells, the sensory cells that normally reside in the inner ear. If they can generate hair cells in the millions, it could lead to significant scientific and clinical advances along the path to curing deafness in the future.

A promising source of creating hair cells comes from induced pluripotent stem cells (iPS)adult cells, taken for example from a patients own skin that have been genetically reprogrammed to revert back to stem cells. This breakthrough process represents a major opportunity to eventually treat a patient with his or her own cells.

Currently, our research team is working toward producing human hair cells for the first time in a culture dish. This work could lead, in the long run, to novel therapies based on cell transplantation.

Equally exciting is an ongoing approach to use embryonic stem cell-based approaches for discovery of novel drugs that could be used for treatment for deafness. More about this exciting new direction can be found under Molecular Therapy.

Originally posted here:
Stem Cell Therapy | Stanford Initiative to Cure Hearing Loss

Novel stem cell therapy for repair of knee cartilage – Mayo …

Dec. 29, 2018

Mayo Clinic offers a unique regenerative medicine approach for repairing knee cartilage, which can be completed in a single surgery. The Food and Drug Administration approved the use of this technique, known as recycled cartilage auto/allo implantation (RECLAIM), in a trial utilizing the stem cell bank in the Mayo Clinic Center for Regenerative Medicine.

"Mayo is unique in having an adipose-derived allogeneic stem cell bank. It provides us with donor mesenchymal stem cells, which we mix with recycled autologous cells to quickly obtain enough cells to fill the patient's cartilage defect without operating twice," says Daniel B. Saris, M.D., Ph.D., an orthopedic surgeon at Mayo Clinic in Rochester, Minnesota, who specializes in knee surgery and focuses on regenerative medicine.

Close

RECLAIM mixes chondrons from debrided tissue with donor autologous stem cells to create a biologic filler for the repair of damaged knee cartilage. The procedure can be completed in a single surgery.

Dr. Saris previously performed the RECLAIM cartilage repair technique in Europe. "The results, about four years out, are very good comparable to or better than other cell therapies, except these patients achieve normal function after surgery about six months more quickly," he says.

Planning is underway for a clinical trial at Mayo Clinic. RECLAIM is used to repair symptomatic cartilage defects, usually resulting from trauma or an athletic injury. The procedure might be suitable for nonarthritic patients ages 18 to 50 who have fresh cartilage defects.

Existing cell therapy to repair knee cartilage generally involves surgically debriding the cartilage defect and then taking a biopsy of healthy cartilage from the patient. The biopsy is cultured in an outside laboratory, and the cultured cells are implanted weeks later. "We wanted to improve this technique because during the waiting period, the patient's life is on hold, costs increase and the logistics can be complex," Dr. Saris says.

RECLAIM's innovation starts with saving the patient's debrided tissue. "That tissue is always a bit frilly and is normally discarded," Dr. Saris says. "But we found that the cells in that tissue are still very viable. We recycle them."

The resected tissue is processed and, using a rapid isolation protocol, digested into chondrons. Mixing the chondrons with allogeneic stem cells from the stem cell bank provides sufficient cells to immediately re-inject into the patient.

"This is a highly innovative procedure," Dr. Saris says. "You have to find an intricate balance loading enough cells to grow into healthy tissue but not overloading the space so the cells are squished when the patient starts rehab."

Most patients return home on the day of surgery. They generally need to wait nine to 12 months before a full return to sports; that interval provides time for the cartilage to grow and the patient to regain muscle control. "But apart from sports, patients can go back to normal life within days and physical activities within three to four months of surgery," Dr. Saris says.

Mayo Clinic's multidisciplinary approach provides the range of care needed by patients at all stages of knee cartilage repair. Before surgery, advanced imaging helps pinpoint the cartilage defect. "Our physiotherapists and athletic trainers also determine prior to surgery how we can optimize the patient's musculoskeletal control and function, and then work with the patient on rehab after surgery," Dr. Saris says.

Mayo Clinic also has the breadth of orthopedic expertise to manage problems that patients often experience alongside damaged knee cartilage, such as varus deformity and anterior cruciate ligament or meniscus lesions. "If a cartilage repair procedure fails, it's generally because not enough attention was paid to other factors the meniscus or the knee's alignment or stability," Dr. Saris says. "Our unique multidisciplinary team looks at all aspects of a patient's care. Our chances of success for these complex biological reconstructions is therefore high."

The cartilage repair technique illustrates Mayo Clinic's commitment to applying regenerative medicine to orthopedic surgery. "We are focused on patient-centered progress," Dr. Saris says. "We want to make sure there is a safe and efficacious portfolio of regenerative medicine therapies for musculoskeletal problems."

Read the original post:
Novel stem cell therapy for repair of knee cartilage - Mayo ...

‘I’m not losing my boy,’ sobs mum after son is diagnosed with cancer for third time – Mirror Online

The Peers family were overjoyed when doctors told them Callum had beaten cancer.

Life returned to normal but, tragically, it would not stay that way.

The battling ten-year-old, who has twice successful fought cancer, has the disease once again.

This time the odds are heavily stacked against him. Doctors here give him just a ten per cent chance of living more than five years.

But his parents are determined to fight on and are pinning their hopes on pioneering drug trials.

They are trying to raise 150,000 to get Callum treatment in the US that is not available on the NHS.

Callums mum Nicola, 37, said: Seeing my son fight this disease for seven years has been heartbreaking but he has never given up.

Hes fought it and beaten it twice and I know he can do it again. We must give him that chance. I am not losing my boy.

Callum, of Leigh, Gtr Manchester, was just three when he began getting symptoms. Nicola first took Callum to his GP with stomach pains.

In June 2013, after hed turned four, he was diagnosed with an aggressive stage-4 neuroblastoma.

She said: It was such a shock when they told us, the last thing we expected. It was a body blow.

I was heartbroken but I had to carry on and be strong for Callum.

We told him he had a lump in his tummy and was having medicine for it. He was a little hero and never complained.

Callum had an operation to remove a tumour in his stomach and gruelling chemotherapy, immunotherapy and stem cell treatment.

He lost his hair, endured sickness, lethargy, high temperatures and spent months in hospital.

Then, in December 2014, the family got the news they were hoping for when his scans came back all clear.

Nicola recalled: We were over the moon. Life slowly went back to normal and we started going on family caravan holidays again.

But just over two years later, in January 2017, when Callum was getting ready for school he complained of feeling unwell.

Nicola noticed a lump on his neck. An emergency scan at the hospital confirmed the cancer had returned.

Nicola said: To get that news a second time was devastating. It could easily have broken us, but we had to fight on.

Callum had three types of chemo and after 12 months in and out of hospital he had kicked the cancer again.

But in August last year there was a lump on his neck and Nicola knew what to expect. The cancer had spread to the right side of his stomach. She said: Id thought after his treatment had finished the second time we were going to go back to normal.

Being told again and again your boy has cancer is awful.

Since then a tumour on Callums chest has been surgically removed and, days before his tenth birthday, another growing on his spine, which could have paralysed him, was taken out.

He has been through more chemo and radiotherapy, been rushed into intensive care with complications four times.

He spent his Christmas at Great Ormond Street hospital in London. Nicola said: Callum is the definition of a fighter. I know he can beat this again and beat it for good.

Treatment options in the UK for Callum have run out but Nicola and his dad Alan, 56, brothers Jake, 19, Joshua, 18, and Cameron, nine, and sister Bethany, 17, arent giving up hope.

Helen Devos Childrens Hospital in Michigan is one of the few centres offering a treatment that works by targeting specific cancer stem cell pathways. Nicola spoke to consultants there and said: Children are going over there and are still clear of disease years and years later.

Callum has been through so much. He just carries on and he deserves this chance.

Were all feeling really hopeful. Its been proven to work.

She added: I know Callum can win his fight if we can give him the best possible chance.

Originally posted here:
'I'm not losing my boy,' sobs mum after son is diagnosed with cancer for third time - Mirror Online

Canine Stem Cell Therapy Market to Witness Growth Acceleration During 2029 – Monroe Scoop

Canine Stem Cell Therapy Market size will reach xx million US$ by 2029, from xx million US$ in 2018, at a CAGR of xx% during the forecast period. In this study, 2018 has been considered as the base year and2029 as the forecast period to estimate the market size for Canine Stem Cell Therapy.

This industry study presents the Canine Stem Cell Therapy Market size, historical breakdown data 2014-2019 and forecast 2029. The Private Plane production, revenue and market share by manufacturers, key regions and type; The consumption of Canine Stem Cell Therapy Market in volume terms are also provided for major countries (or regions), and for each application and product at the global level.

ThisPress Release will help you to understand the Volume, growth with Impacting Trends. Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) at https://www.xploremr.com/connectus/sample/2360

Canine Stem Cell Therapy Market report coverage:

The Canine Stem Cell Therapy Market report covers extensive analysis of the market scope, structure, potential, fluctuations, and financial impacts. The report also enfolds the precise evaluation of market size, share, product & sales volume, revenue, and growth rate. It also includes authentic and trustworthy estimations considering these terms.

The Canine Stem Cell Therapy Market has been reporting substantial growth rates with considerable CAGR for the last couple of decades. According to the report, the market is expected to grow more vigorously during the forecast period and it can also influence the global economic structure with a higher revenue share. The market also holds the potential to impact its peers and parent market as the growth rate of the market is being accelerated by increasing disposable incomes, growing product demand, changing consumption technologies, innovative products, and raw material affluence.

The study objectives are Canine Stem Cell TherapyMarket Report:

In this study, the years considered to estimate the market size of Canine Stem Cell TherapyMarket:

History Year: 2014 2018

Base Year: 2018

Estimated Year: 2019

Forecast Year:2029

This report includes the estimation of market size for value (million USD) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Canine Stem Cell Therapy Market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Get Your Copy at a Discounted Rate!!! Limited Time Offer!!! https://www.xploremr.com/connectus/check-discount/2360

The report covers exhaustive analysis on:

Regional analysis includes

Get Full Report Access athttps://www.xploremr.com/cart/2360/SL

Benefits of Purchasing from XMR:

About Us

XploreMR is one of the worlds leading resellers of high-quality market research reports. We feature in-depth reports from some of the worlds most reputed market research companies and international organizations. We serve across a broad spectrum from Fortune 500 to small and medium businesses. Our clients trust us for our unwavering focus onquality and affordability. We believe high price should not be a bottleneck for organizations looking to gain access to quality information.

Contact us:

XploreMR111 North Market Street, Suite 300,San Jose, CA 95113, United StatesPh.No: +16692840108E-mail id-[emailprotected]Web-https://www.xploremr.com

Read the original:
Canine Stem Cell Therapy Market to Witness Growth Acceleration During 2029 - Monroe Scoop